프리마켓
로그인 회원가입
JUNS
JUNS
Jupiter Neurosciences Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$0.11
-0.01 ▼ -6.20%
🌙 7월 28일 6:08 AM ET (한국 7/28 19:08)
$0.11
+0.00 -1.68%

주피터 뉴로사이언스(JUNS) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$5M
스몰캡
P/E
-
배당수익률
없음
52주 위치
0%
저점 +3% · 고점 -94%
애널리스트
적극 매수
F
Fundamental health
vs. Biotechnology 초소형주· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 74%
밸류에이션
데이터 부족
재무 안정
Top 100%
Index -P/E -EPS (ttm) -0.27Insider Own 36.98%Shs Outstand 36.3MPerf Week -31.21%
Market Cap 0.01BForward P/E -EPS next Y -Insider Trans -Shs Float 30.4MPerf Month -52.03%
Enterprise Value 0.01BPEG -EPS next Q -Inst Own 3.95%Short Float 0.79%Perf Quarter -70.9%
Income -0.01BP/S 136.95EPS this Y -Inst Trans 4.35%Short Ratio 0.02Perf Half Y -87.25%
Sales 0.00BP/B -EPS next 5Y -ROA -205.98%Short Interest 0.24MPerf YTD -88.87%
Book/sh -0.08P/C 2.32EPS past 3/5Y -18.29% -7.78%ROE -6529.17%52W High -93.83% ($1.84)Perf Year -92.99%
Cash/sh 0.05P/FCF -Sales past 3/5Y -ROIC -52W Low 3.18% ($0.11)Perf 3Y -
Dividend Est. -EV/EBITDA -EPS Y/Y TTM -166.53%Gross Margin 78.76%Volatility(W/M) 34.04% 15.6%Perf 5Y -
Dividend TTM -EV/Sales 199.45Sales Y/Y TTM -Oper. Margin -23075.85%ATR (14) 0.03Perf 10Y -
Dividend Ex-Date -Quick Ratio 0.48EPS Q/Q -26.62%Profit Margin -22690.83%RSI (14) 24.27Recom 1
Dividend Gr. 3/5Y -Current Ratio 0.51Sales Q/Q -SMA20 -37.97% ($0.18)Beta 1.98Target Price $25
Payout -Debt/Eq -Earnings -SMA50 -49.99% ($0.22)Rel Volume 0.19Prev Close $0.12
Employees 5LT Debt/Eq -EPS/Sales Surpr. -SMA200 -83.46% ($0.67)Avg Volume(3M) 13.50MPrice $0.11
IPO 2024/12/3Option/Short No/YesTrades 1416Volume 2,626,605Change -6.2%
Quarterly earnings trend SEC filings · USD
23.9
24.3
24.6
24.9
25.3
25.6
25.9
26.3
Revenue Net income 최근 분기: 매출 $0M · 순이익 $-2M (YoY -35%)

📊 Jupiter Neurosciences Inc (JUNS) Investment Analysis

What kind of company is Jupiter Neurosciences Inc?

주피터 뉴로사이언스(JUNS)
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

🧠 Jupiter Neurosciences is a clinical-stage biotech company targeting central nervous system (CNS) disorders with JOTROL™, its patented micellar delivery platform for resveratrol. The company highlights over 9x higher bioavailability compared to conventional resveratrol and is expanding into rare CNS indications such as Parkinson's disease, Alzheimer's, Friedreich's ataxia, and MELAS. Using the same technology, it also operates the Nugevia™ nutraceutical brand.

Learn more about Jupiter Neurosciences Inc →
Market Cap
$0.0B
Approx. KRW 0.0 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank5641
Employees5people
IPO2024/12/03
Current Price$0.11 ≈ 151원
NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2025년 12월 3일 (수) · 장 마감 후 EPS +0.0%

Is it profitable?

Both profitability & finances need caution
Review management risk carefully before investing
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-23075.8%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Net Margin
Share of revenue left after taxes and interest are paid
-22690.8%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
78.8%
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology 초소형주 Median 53.4% · Top 31%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-6529.2%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-206.0%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Current Ratio
Liquid assets available to cover liabilities due within a year
0.51
✓ 매우 부진
My positionBottom 5%
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
0.48
✓ 매우 부진
My positionBottom 5%
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$25.00
현재가 대비 +22627.3%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance
Generally in line with estimates
0
예상 상회
1
예상 부합
0
예상 하회
0%
상회 비율
+0.0%
평균 서프라이즈
2025.12.03
부합
+0.0%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
-18.3%
부진
My positionBottom 25%
Low range Average High range
미분류 초소형주 Median 25.4% · Bottom 24%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
-7.8%
평균
My positionMid-range
Low range Average High range
미분류 초소형주 Median 14.6% · Bottom 28%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Underperformed the market by 109%p over the past year
JUNS -93.0% · S&P 500 +16.0%
Excess return vs. market (price-based, ex-dividends)
1-year basis
vs S&P 500
-109.0%p
Significantly behind the market
vs Health Care (XLV)
-112.7%p
Significantly behind the sector average
Rank among peers
1-year return Lowest among peers Based on 315 peers
Current position within 52-week range
Low (-3.2%p) High (-93.8%p)
Current price is 3.2% above the 52-week low and 93.8% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-82.3%
Annualized volatility
135.7%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔵
Current diagnosis · 2026-07-27
Oversold zone — rebound potential

Current price $0.11 fell below the lower band ($0.12). Selling pressure excessive; worth watching for a short-term bounce. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴
Current diagnosis · 2026-07-27
Bearish momentum holding

MACD -0.029 < Signal -0.024 in negative zone + Hist negative (-0.005). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔵
Current diagnosis · 2026-07-27
Oversold zone — rebound potential

RSI 23.5 (30 or below). Selling pressure is excessive; a short-term rebound may be worth considering. Stoch %K is also 0.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry
Pricey on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🧾 Vs. Sales Pricey
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
136.95x
✓ Pricey
My positionBottom 25%
Low range Average High range
Biotechnology 초소형주 median 11.24x · Bottom 18% — expensive within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
Analyst target price (reference)
$25.00 vs. current price +22627.3%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership flow is positive
Institutional net buying +4.3% · Short interest light 0.8% · Short interest fell -0.7%p over the last 90 days
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
+4.3%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 4.0%
Retail-led
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 37.0%
Founder/management large holders (strong skin-in-the-game)
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 59.1%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
0.8%
Low — limited short-side pressure
Healthcare 초소형주 Median 3.9%
Past 90 days 📉 -0.7%p decrease
Short interest days to cover
0.0 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 36.3M주
Float (tradable shares) 30.4M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding JUNS

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
JUNS JUNS This Stock
$5.5M- - -6529.17% - -6.2%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 주피터 뉴로사이언스(JUNS)?

주피터 뉴로사이언스(JUNS) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of JUNS?

The market cap of JUNS is approximately $5M, ranking 5,641 within its sector.

What is the 52-week high and low for JUNS?

JUNS has recorded a 52-week high of $1.84 and a low of $0.11.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.